Previous close | 69.50 |
Open | 69.50 |
Bid | 70.50 x 0 |
Ask | 71.00 x 0 |
Day's range | 69.50 - 69.50 |
52-week range | 61.26 - 79.64 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.